Despite these findings, a phase II clinical trial of a different HDAC inhibitor, panobinostat, in 20 patients with refractory ccRCC, failed to show an objective response (Hainsworth et al., 2011). Here, HDAC9 is linked to nonpapillary renal cell carcinoma.